SpringLeaf Therapeutics, Inc. — Form D/A
SpringLeaf Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2011-07-08. The offering totals $19.0M, of which $19.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2011-07-08
- Form: D/A
- Accession: 0001413681-11-000005
- Industry: Pharmaceuticals
- Exemptions: 06
- Total offering: $19.0M
- Amount sold: $19.0M
- Investors: 8
- Date of first sale: 2011-04-28
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-159732
Issuer
- Name: SpringLeaf Therapeutics, Inc.
- CIK: 0001413681
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2007
- Address: 8 ST. MARY'S STREET, BOSTON, MA, 02215
- Phone: 617-358-4927
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Frank Bobe | Director | Boston, MA |
| Garen Bohlin | Director | Stoughton, MA |
| Yet-Ming Chiang | Director | Somerville, MA |
| Michael Cima | Director | Cambridge, MA |
| Brian Gallagher | Director | New York, NY |
| Kurt Graves | Director | Hayward, CA |
| Michael Greeley | Director | Boston, MA |
| Jeffrey McCarthy | Director | MALDEN, MA |
| Frank Bobe | Executive Officer | Boston, MA |
| Glenn Larsen | Executive Officer | Boston, MA |
Other filings by this issuer (1)
More